ABVC BioPharma, Inc. (ABVC) Stock Price & Analysis
ABVC BioPharma, Inc. (ABVC) — MoonshotScore 32/100 (Weak band), calculated Nov 18, 2026. Price $0.88 (-3.34%), as of the Nov 19, 2026 trading session; market cap $23.7M.
Educational signal · not a buy or sell recommendation · How to read this
ABVC BioPharma, Inc. · ABVC · NASDAQ
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs and medical devices to address unmet medical needs. They have multiple drug candidates in various stages of clinical trials, targeting conditions like cancer, depression, and ADHD.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · ABVC BioPharma (ABVC)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a fragile balance sheet, stalling growth and a full valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and reported profit not backed by cash flow. Business Quality: Solid; Financial Safety: Fragile; Valuation: Full; Growth Durability: Shrinking; Momentum: Quiet.
- quarterly revenue -$795,950 (Q4 FY2025, quarter ended Dec 2025)
- EPS beat 0 of the last 4 reports
- Altman Z -5.16 · Piotroski F 2
Holding back: balance-sheet strain, soft growth
Helping: business quality
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 30 | Weak | |
| 30 | Weak | |
| 30 | Weak | |
| 30 | Weak | |
| 32 | Weak | |
| 32 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.88 | |
| Change on the day | -3.34% | |
| 52-week range | $0.7069 – $3.06 | |
| Market capitalisation | $23.7M | — |
| Shares traded on the day | 57.5K |
Price & events
Other perspectives
Council score for ABVC BioPharma (ABVC): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is ABVC BioPharma (ABVC), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. ABVC BioPharma, Inc. (ABVC) is listed on NASDAQ. It employs 18 people and is led by Uttam Yashwant Patil. In Q4 FY2025 it reported revenue of -$795,950 and net income of -$4M. The market values it at $23.7M.
What do the latest results show for ABVC BioPharma (ABVC)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of -$795,950. Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 1 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | -$795,950 | -$4M | — |
What are the financial strengths and risks for ABVC BioPharma (ABVC)?
Short answer
The MoonshotScore pillars rate business quality as strengths. What is holding it back is balance-sheet strain, soft growth. The distress and quality screens read Altman Z -5.16 · Piotroski F 2. Trailing ratios: ROE -71.5% · ROA -40.7% · current ratio 0.07 · earnings yield -31.3% · free-cash-flow yield -9.5%.
Data-derived red flags
- Listing risk — at $0.88 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -5.16 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-71.5%) — the business is not currently generating profit on shareholder capital.
What should you watch next at ABVC BioPharma (ABVC)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $35.28M · EPS 1.30 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q4 FY2025) was filed Mar 3, 2026 — 8 months ago.
Checked against the records this page reads, on the dates shown above.
How does ABVC BioPharma compare with its peers?
Short answer
ABVC BioPharma's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $12.17 Nov 19, 2026 | $861M | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $30.78 Nov 19, 2026 | $1.03B | 64 5-pillar Nov 18, 2026 | |
| $8.14 Nov 19, 2026 | $796M | 63 5-pillar Nov 18, 2026 | |
| ABVC BioPharma (ABVC) — this page | $0.88 | $23.7M | 32 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $35.28M
- EPS estimate
- $1.30
Measured against a quoted price of $0.88 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 8
- Purchases
- 4
- Sales
- 0
- Other transactions
- 8
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ABVC in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ABVC in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about ABVC BioPharma (ABVC)?
- ABVC BioPharma Reports Q3 2026 Financial Results
- ABVC BioPharma Closes $3.39 Million Convertible Note Offering and Settles Financing Dispute
- ABVC BioPharma Announces Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 Million
Common Questions About ABVC
These answers are editorial: 1 of these 9 answers is drawn from the ABVC research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ABVC?
ABVC carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is ABVC a good stock to buy?
Stock Expert AI does not rate ABVC buy, sell or hold. ABVC BioPharma, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ABVC stock price today?
The last price recorded for ABVC BioPharma, Inc. (ABVC), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does ABVC BioPharma, Inc. do?
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing drugs and medical devices that address unmet medical needs.
What are the key factors to evaluate for ABVC?
ABVC BioPharma, Inc. (ABVC) holds a MoonshotScore in the low range. ABVC BioPharma has a co-development agreement with Rgene Corporation, enhancing its R&D capabilities and pipeline development. Not financial advice.
How frequently does ABVC data refresh on this page?
ABVC's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ABVC's recent stock price performance?
ABVC BioPharma, Inc. (ABVC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse pipeline of drug candidates in various stages of clinical trials. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ABVC overvalued or undervalued right now?
ABVC BioPharma, Inc. (ABVC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ABVC?
Fractional-share availability for ABVC BioPharma, Inc. (ABVC) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 19 figures on this page — 9 from Financial Modeling Prep (FMP), 9 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com